Nalu Medical, Inc., a privately held commercial medical device company, has announced it has secured $85.0 million in new investment capital. This substantial funding round highlights robust investor confidence in the company's innovative neurostimulation technology and its growing potential within the expansive chronic pain management market.
Based in Carlsbad, California, Nalu Medical is known for its Nalu neurostimulation system. This system features a battery-free, micro-implantable pulse generator (iPG) that has received FDA clearance for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). The technology is designed to mitigate chronic pain, offering a highly capable and easily upgradeable system with a diverse menu of therapy options for patients and clinicians.
The $85.0 million investment is expected to significantly fuel Nalu Medical's strategic growth initiatives and operational expansion. While specific allocation details were not publicly disclosed, the capital will likely be directed towards scaling commercial operations, advancing ongoing research and development efforts to further enhance its neurostimulation platform, and achieving broader market penetration for its innovative pain management solutions. This substantial funding round is critical for Nalu Medical as it seeks to accelerate its mission of providing advanced, less invasive, and effective options for individuals suffering from chronic pain.
This significant capital infusion is poised to strengthen Nalu Medical's competitive market presence and enable the company to substantially scale its operations and reach. The company plans to leverage this investment to continue its trajectory of innovation within the neurostimulation space, aiming to expand access to its technology for more patients and solidify its position as a leader in developing advanced, patient-centric solutions for chronic pain management globally.
